Sawyer Jason David 4

What Happened
Jason David Sawyer, a director of Lixte Biotechnology Holdings, had 25,000 stock options canceled on April 15, 2026 and, in exchange, was granted 25,000 restricted stock units (RSUs). The RSUs vest immediately upon grant; each RSU represents a contingent right to one share of common stock upon settlement. The filing shows the option cancellation as a derivative disposition and the RSU grant as an acquisition (award). No dollar price per share was reported (N/A).

Key Details

• Transaction dates: April 15, 2026 (grant of 25,000 RSUs; cancellation/disposition of 25,000 options).
• Transaction codes: A = Award/Grant of 25,000 RSUs; D = Disposition to issuer of 25,000 options (derivative).
• Price: N/A (no cash purchase or open-market sale reported).
• Vesting: The 25,000 RSUs vest immediately upon grant (per the award agreement).
• Prior option info: The canceled options were originally granted Aug 15, 2025; their prior vesting schedule was 50% on the effective date and the remainder in quarterly installments (see filing footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Report filed Apr 17, 2026 covering Apr 15, 2026 transactions — appears to have been filed within the normal Form 4 reporting window.

Context
This was not a cash purchase or an open-market sale. Instead, it’s an internal exchange—options were canceled and replaced with RSUs that are already vested, giving the insider an immediate right to receive shares upon settlement under the RSU award terms. For retail investors, awards and restructurings like this generally reflect compensation or retention actions rather than a direct buying or selling signal.